| Literature DB >> 30770700 |
Xiaolou Huang1,2, Shuwen Guo1, Fanghe Li1, Xiaobo Tan1, Qian Cai1, Hui Wang1, Panbi Chen2, Guohua Wang3, Xiaona Ma4.
Abstract
BACKGROUND In traditional Chinese medicine, acupuncture has been used to treat angina due to coronary artery disease (CAD). The aim of this systematic review of the literature and meta-analysis was to identify published randomized controlled trials (RCTs) that quantified the effectiveness of adjunctive acupuncture treatment in patients with angina due to CAD who were also treated with Western or Chinese medicine. MATERIAL AND METHODS A systematic review of the literature included a search of the PubMed, Embase, Cochrane library, and China National Knowledge Infrastructure (CNKI) databases, from their inception to September 2018. Published findings from RCTs were included that investigated the effectiveness of acupuncture as an adjunctive treatment for angina due to CAD in combination with Western or traditional Chinese medicine. The odds ratio (OR) and 95% confidence interval (CI) were calculated using the random-effects model to determine the outcomes of markedly and moderately effective rates for the use of acupuncture. RESULTS Twenty-four published RCTs were identified that included 1,916 patients with CAD. Patients who received adjunctive acupuncture treatment had a significantly increased markedly effective rate. However, the moderately effective rate between adjunctive acupuncture combined with standard treatment for angina and standard treatment alone was not statistically significant. Sensitivity analysis showed that the pooled results for the markedly and moderately effective rates were robust. Subgroup analysis in most subsets supported the main findings. CONCLUSIONS Meta-analysis supported a positive treatment effect for the use of acupuncture when used as adjunctive therapy in patients with angina due to CAD.Entities:
Mesh:
Year: 2019 PMID: 30770700 PMCID: PMC6390455 DOI: 10.12659/MSM.913379
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Flowchart of the literature search and publication selection process.
Baseline characteristic of studies included in the meta-analysis.
| Study | Publication year | Sample size | Mean age (years) | Percentage male (%) | Duration of disease | Background therapy | Duration of treatment | JADAD scale |
|---|---|---|---|---|---|---|---|---|
| Han [ | 1999 | 70 | 58.1 | 60.0 | 7.8 years | Isosorbidedinitrate 10 mg×3/day | 1.0 month | 2 |
| Cao [ | 2002 | 51 | 63.4 | 23.5 | 4.8 years | Isosorbidedinitrate 5–10 mg×3/day; aspirin 50–300 mg×3/day | 15 days | 1 |
| Tong [ | 2005 | 200 | 62.9 | 57.5 | 1.9 years | Aspirin 150 mg; 5-Nitor sorbitol ester 40 mg/day, metoprolol 25 mg×2/day, simvastatin 20 mg/day | 1.0 month | 1 |
| Yu [ | 2005 | 63 | 51.5 | 46.0 | 2.0 months–22.0 years | Nitroglycerin 5mg/day | 14 days | 2 |
| Wang [ | 2006 | 62 | 63.6 | 45.2 | NA | Aspirin 50 mg/day, metoprolol 12.5–25 mg/day, Isosorbide nitrate 10mg/day | 1.0 month | 2 |
| Liu [ | 2006 | 62 | 57.5 | 82.3 | 2.1 years | 5-Isosorbidemononitrate 20mg twice/day, diltiazem hydrochloride 30 mg 3 times/day and aspirin 50mg/day | 1.0 month | 2 |
| Sun [ | 2007 | 108 | 32–76 | 63.0 | 0.5 months–12.0 years | Nitroglycerin 1mg/day, and diltiazem 60 mg 3 times/day | 14 days | 2 |
| Liu [ | 2007 | 105 | 60.5 | 62.9 | 6.4 years | Isosorbidedinitrate 10 mg×3/day, metoprolol 12.5 mg×2/day, nifedipine 10 mg×2/day, and simvastatin 10 mg/day | 10 days | 2 |
| Jin [ | 2010 | 93 | 54.1 | 60.2 | 2.0 months–25.0 years | Metoprolol 12.5 mg×2/day, aspirin 50 mg/day, simvastatin 10 mg/day | 14 days | 1 |
| Liang [ | 2011 | 120 | 49.0 | 44.2 | NA | Traditional Chinese medicine | 1.0 month | 2 |
| Xie [ | 2012 | 67 | 60.6 | 61.2 | NA | Isosorbidedinitrate 10–60 mg×3/day | 1.0 month | 2 |
| Li [ | 2012 | 90 | 58.1 | 47.8 | 10.0 months–12.0 years | Nitrates, aspirin, and β receptor blocker | 1.0 month | 2 |
| Du [ | 2013 | 80 | 59.4 | 62.5 | NA | Metoprolol, aspirin, heparin | NA | 1 |
| Zhao [ | 2013 | 60 | 60.0 | 48.3 | 7.9 years | Isosorbidemononitrate 50 mg/day, trimetazidinedihydrochloride 20 mg×3/day | 20 days | 2 |
| Li [ | 2013 | 40 | 59.9 | 35.0 | NA | Traditional Chinese medicine | 1.0 month | 2 |
| Liu [ | 2014 | 65 | 53.9 | 67.7 | NA | Traditional Chinese medicine | 1.0 month | 2 |
| Guo [ | 2014 | 68 | 49.9 | 57.4 | 3.0 months–15.0 years | Isosorbidemononitrate 20 mg/day, aspirin 80 mg/day | 14 days | 2 |
| Li [ | 2015 | 51 | 45.9 | 27.5 | 3.4 years | Isosorbidedinitrate 5–10 mg×3/day; aspirin 50–300 mg×3/day | 30 days | 2 |
| Xie [ | 2016 | 80 | 55.1 | 70.0 | NA | Traditional western medicine | NA | 2 |
| Jia [ | 2016 | 60 | 58.6 | 46.7 | NA | Aspirin 100 mg/day, metoprolol 6.25–25 mg/day, Isosorbide nitrate 10 mg×3 times/day, atorvastatin 10 mg/day | 1.0 month | 2 |
| Tan [ | 2016 | 65 | 65.1 | 47.7 | 7.3 years | Traditional Chinese medicine | 1.0 month | 2 |
| Lin [ | 2016 | 90 | 51.9 | 48.9 | 10.4 years | Traditional Chinese medicine | 2.0 months | 2 |
| Zhou [ | 2017 | 90 | 59.3 | 46.7 | 4.1 years | Traditional Chinese medicine | 1.0 month | 2 |
| Deng [ | 2018 | 76 | 56.8 | 64.5 | 1.7 years | Nitrates, β-blockers, ca-antagonists, angiotensin converse enzyme inhibitors | 1.0 month | 2 |
Figure 2Effect of acupuncture as adjunctive therapy on the incidence of the markedly effective rate.
Figure 3Sensitivity analysis for the markedly effective rate.
Subgroup analysis for markedly effective rate.
| Subgroups | Number of cohorts | OR (95% CI) | |||
|---|---|---|---|---|---|
| Publication year | |||||
| Before 2010 | 8 | 2.11 (1.38–3.23) | 0.001 | 35.0 (0.149) | 0.867 |
| 2010 or after | 16 | 2.11 (1.51–2.96) | <0.001 | 41.3 (0.043) | |
| Sample size | |||||
| ≥100 | 4 | 2.12 (0.92–4.89) | 0.079 | 75.9 (0.006) | 0.861 |
| <100 | 20 | 2.10 (1.61–2.73) | <0.001 | 20.4 (0.202) | |
| Mean age (years) | |||||
| ≥60.0 | 7 | 2.86 (1.77–4.61) | <0.001 | 40.7 (0.120) | 0.152 |
| <60.0 | 16 | 1.85 (1.35–2.54) | <0.001 | 33.2 (0.096) | |
| NA | 1 | 1.59 (0.62–4.09) | 0.332 | – (–) | |
| Percentage of male patients (%) | |||||
| ≥60.0 | 10 | 2.24 (1.30–3.87) | 0.004 | 63.5 (0.003) | 0.687 |
| <60.0 | 14 | 1.98 (1.53–2.56) | <0.001 | 0.0 (0.566) | |
| Disease duration (years) | |||||
| ≥2.0 | 9 | 2.44 (1.67–3.56) | <0.001 | 17.1 (0.290) | 0.380 |
| <2.0 | 2 | 2.23 (1.29–3.87) | 0.004 | 0.0 (0.459) | |
| NA | 13 | 1.88 (1.26–2.82) | 0.002 | 50.5 (0.019) | |
| Background therapy | |||||
| Western medicine | 18 | 2.16 (1.59–2.92) | <0.001 | 39.1 (0.046) | 0.527 |
| Chinese medicine | 6 | 1.95 (1.15–3.32) | 0.014 | 37.9 (0.153) | |
| Treatment duration (month) | |||||
| 1.0 | 15 | 2.05 (1.57–2.66) | <0.001 | 5.5 (0.391) | 0.952 |
| <1.0 | 9 | 2.12 (1.23–3.68) | 0.007 | 62.8 (0.006) | |
| JADAD scale | |||||
| 2 | 20 | 2.11 (1.53–2.90) | <0.001 | 46.1 (0.013) | 0.855 |
| 1 | 4 | 2.12 (1.41–3.19) | <0.001 | 0.0 (0.791) | |
Figure 4Effect of acupuncture adjunctive therapy on the incidence of the moderately effective rate.
Figure 5Sensitivity analysis for the moderately effective rate.
Subgroup analysis for moderate effective rate.
| Subgroups | Number of cohorts | OR (95% CI) | |||
|---|---|---|---|---|---|
| Publication year | |||||
| Before 2010 | 8 | 0.87 (0.58–1.32) | 0.524 | 33.4 (0.161) | 0.501 |
| 2010 or after | 15 | 1.04 (0.81–1.33) | 0.768 | 0.0 (0.449) | |
| Sample size | |||||
| ≥100 | 4 | 0.74 (0.38–1.46) | 0.385 | 66.4 (0.030) | 0.306 |
| <100 | 19 | 1.05 (0.83–1.32) | 0.682 | 0.0 (0.663) | |
| Mean age (years) | |||||
| ≥60.0 | 6 | 0.87 (0.46–1.63) | 0.654 | 60.7 (0.026) | 0.603 |
| <60.0 | 16 | 0.99 (0.78–1.26) | 0.958 | 0.0 (0.735) | |
| NA | 1 | 1.42 (0.63–3.20) | 0.403 | – (–) | |
| Percentage of male patients (%) | |||||
| ≥60.0 | 9 | 1.12 (0.72–1.76) | 0.613 | 46.9 (0.058) | 0.271 |
| <60.0 | 14 | 0.90 (0.71–1.15) | 0.420 | 0.0 (0.797) | |
| Disease duration (years) | |||||
| ≥2.0 | 9 | 0.87 (0.55–1.37) | 0.539 | 39.2 (0.102) | 0.727 |
| <2.0 | 2 | 0.96 (0.59–1.56) | 0.863 | 0.0 (0.701) | |
| NA | 12 | 1.06 (0.81–1.38) | 0.682 | 0.0 (0.452) | |
| Background therapy | |||||
| Western medicine | 17 | 0.97 (0.75–1.25) | 0.804 | 20.3 (0.217) | 0.871 |
| Chinese medicine | 6 | 1.02 (0.69–1.49) | 0.927 | 0.0 (0.433) | |
| Treatment duration (month) | |||||
| 1.0 | 14 | 0.98 (0.77–1.25) | 0.874 | 0.0 (0.934) | 1.000 |
| <1.0 | 9 | 0.95 (0.58–1.56) | 0.838 | 57.2 (0.017) | |
| JADAD scale | |||||
| 2 | 19 | 1.00 (0.77–1.30) | 0.990 | 23.2 (0.175) | 0.705 |
| 1 | 4 | 0.92 (0.62–1.36) | 0.677 | 0.0 (0.705) | |
Figure 6Funnel plot for the markedly effective rate.
Figure 7Funnel plot for the moderately effective rate.